Chronic Kidney Disease in Primary Care

Chronic Kidney Disease
Christos Argyropoulos MD, PhD
University of New Mexico School
of Medicine

Overview
• Chronic Kidney Disease Basics
• Review ACP guidelines for CKD care
• Interface between Primary Care &
Nephrology
–Special considerations in diabetes,
hypertension, CVD and CKD
–Drug dosing considerations
–What do nephrologists/CKD clinic do?
–CKD “cheat-sheet”

1. Burden of chronic kidney disease (CKD) and kidney
failure
2. Back to the basics
 Renal anatomy, physiology, and functional
assessment
 “Numerology” of Nephrology (eGFR/proteinuria)
 Identify and monitor CKD progression
Chronic kidney disease basics

 Chronic Kidney Disease
− Kidney function
 Glomerular filtration rate (GFR) < 60 mL/min/1.73 m2 for > 3
months with or without kidney damage
AND/OR
− Kidney damage
 > 3 months, with or without decreased GFR, manifested by either
− Pathological abnormalities
− Markers of kidney damage, i.e., proteinuria (albuminuria)
» Urine albumin-to-creatinine ratio (UACR) > 30 mg/g
CKD is reduced kidney function
and/or kidney damage
Reference: National Kidney Foundation Kidney Disease Outcome Quality Initiative
(KDOQI). Clinical practice guidelines for chronic kidney disease: evaluation,
classification, and stratification. Amer J Kid Dis 2002; 39(2 suppl 1):S18–S266.

 Kidneys cannot maintain homeostasis.
 Kidney failure is associated with fluid, electrolyte,
and hormonal imbalances and metabolic
abnormalities.
 ESRD means the patient is on dialysis or has a
kidney transplant.
Kidney failure is an eGFR < 15

Incidence of ESRD is increasing
(and appears to be following obesity trends)
Reference: USRDS Annual Data Report (NIDDK, 2010)

Diabetes is the leading cause
of ESRD, followed by hypertension
Reference: Adapted from USRDS Annual Data Report (NIDDK, 2011)

New Mexico And Hawai Are Sister States
(for Diabetic CKD)

Diabetes is an even more common cause of
CKD in Sandoval County

 Diabetes
 Hypertension
 Family history of kidney disease
 Cardiovascular disease
 Recurrent urinary tract infections
 HIV infection
 Autoimmune diseases
Risk factors for CKD

 Historical cohort study (Kaiser) found that body
mass index (BMI) > 25 is an independent predictor
for ESRD.
 A retrospective 20-year study in Norway found the
risk for CKD increases for pre-hypertensive patients
with BMI > 30.
Overweight may be an independent risk
factor for CKD
References: Hsu et al. Ann Intern Med 2006; 144(1):21–28; Munkhaugen et al. Am J Kid Dis 2009;
54(4):638–646.

CKD (And ESRD) are costly
• Cost of treating ESRD : almost $50B/year
• Cost of treating all CKD: $45.5B/year
• Cost of treating diabetic CKD: $24.6B/year
Reference: Adapted from USRDS Annual Data Report (NIDDK, 2013)

The functions include:
 Filtration
− Glomeruli generate
ultrafiltrate of the plasma.
 Reabsorption
− Tubules selectively
reabsorb substances from
the ultrafiltrate.
 Secretion
− Tubules secrete
substances into the urine.
The nephron functions to maintain balance

 Regulatory function
− Control composition and volume of blood
 Maintain stable concentrations of inorganic anions such as
sodium (Na), potassium (K), and calcium (Ca)
− Maintain acid-base balance
 Excretory function
− Produce urine
− Remove metabolic wastes
 Including nitrogenous waste
The kidneys maintain homeostasis

 Hormone function
− Produce renin for blood pressure control
− Produce erythropoietin which stimulates marrow
production of red blood cells
− Activate 25(OH)D to 1,25 (OH)2D (active vitamin D)
 Metabolic function
− Gluconeogenesis
− Metabolize drugs and endogenous substances
(e.g., insulin)
The kidneys have other functions

 We have a large physiologic reserve.
 Slow, progressive loss of functioning nephrons may
not be noticeable.
 The person with CKD may not feel different.
Each kidney has about 1 million nephrons; slow
loss may not be noticeable

 The composition of the urine changes.
 Most people do not notice any difference in urine
volume.
 Slow, progressive loss of function may not be
noticeable.
People with CKD still make urine

 Damage to the filter allows larger molecular weight
substances such as albumin into the ultrafiltrate.
 Increased urine protein may be a cause as well as a
sign of kidney injury.
Glomerular injury may result in urinary
excretion of larger molecules

 Urine volume may not change
− Composition of the urine changes
 Reduced waste excretion
− May not be apparent until CKD is advanced
 Altered hormone production
− Anemia (erythropoietin) and mineral & bone disorders
(vitamin D)
 Reduced catabolism
− Examples: Insulin, glucagon, drugs
Fewer nephrons disrupt the balance

 Reduced renal clearance and accumulation of:
− Advanced glycation end products
− Pro-inflammatory cytokines
− Reactive oxygen species (oxidation)
− Metabolic acids
 Insulin resistance (even in people without diabetes)
− Reduces insulin-mediated glucose uptake in skeletal
muscles
− May be associated with inflammation as well
Fewer nephrons disrupt the balance

NUMEROLOGY
eGFR and Albuminuria

 GFR is equal to the sum of the filtration rates in all
of the functioning nephrons.
 GFR is not routinely measured in clinical settings.
 Estimation of the GFR (eGFR) gives a rough measure
of the number of functioning nephrons.
What is the glomerular filtration rate (GFR)?

 A typical “normal” reference range of
0.6–1.2 mg/dL listed on many lab reports does not
account for muscle mass, age, gender,
and race.
 A 28-year-old African American man with serum
creatinine of 1.2 has an eGFR > 60.
 A 78-year-old white woman with serum creatinine of
1.2 has an eGFR of 43.
“Normal” serum creatinine
may not be normal

 eGFR is not the measured GFR.
 The formula to estimate GFR was derived from a
population-based study.
 eGFR is based on serum creatinine levels.
 Previous methods to estimate kidney function also
are based on serum creatinine.
 Creatinine assays are now standardized.
− Isotope Dilution Mass Spectrometry (IDMS)
eGFR estimates the measured GFR

Reference Table for Population Mean eGFR from NHANES III
Kidney function and eGFR decline with age
Reference: http://nkdep.nih.gov/professionals/gfr_calculators/gfr_faq.htm
Age (years) Mean eGFR (mL/min/1.73 m2)
20–29 116
30–39 107
40–49 99
50–59 93
60–69 85
70+ 75

Odds Ratio of Nephrology referral in the
absence of automatic eGFR reporting
PLoS ONE 9(11): e112767. doi:10.1371/journal.pone.0112767 (2014)
http://www.plosone.org/article/info:doi/10.1371/journal.pone.0112767
1.13
(mg/dl)
2.26 3.40 4.52
1.7 – 2.8

 Do not use with:
− Rapidly changing creatinine levels
 Example: acute kidney injury
− Extremes in muscle mass, body size, or altered diet
patterns
− Medications that interfere with the measurement of
serum creatinine
 Not all estimating equations are created equal
− MDRD is “blind” above 60 ml/min/1.73m2
Creatinine-based estimates of kidney
function have limitations

Cystatin – C v.s. Creatinine
• Cystatin – C is a “novel”
measure of renal
function
• Estimating equations
have been developed to
use Cys-C alone or with
SCr
• These equations do not
always agree !

 Normal: ≥ 60 mL/min/1.73 m2
 Kidney disease: 15–59 mL/min/1.73 m2
 Kidney failure: < 15 mL/min/1.73 m2
How to explain eGFR results
to patients

 Stable eGFR levels may mean non-progressive
disease or current therapy is working.
 A rapid decline in eGFR may indicate rapid
progression of kidney disease.
 A decline within the “>60” range may not always be
benign (even if the eGFR is technically “normal”)
Monitor the eGFR trends

Proteinuria/Albuminuria
• Though not a measure of GFR, it is a marker of kidney damage
that independently predicts cardiovascular disease.
• It is in the definition of stage 1 and stage 2 CKD.
• Controversial whether microalbuminuria always represents
kidney disease (CKD stage 1) or whether it could reflect
endothelial dysfunction without kidney damage.
• Generally use spot urine for albumin/creatinine ratio- but can
use total protein/creatinine for significant proteinuria (>500-
1000 mg/g).

 Standard of diabetes care (annual screen)
 Diagnosis
− Forty percent of people are identified with CKD on the basis of
urine albumin alone.
− 50% of diabetics with CKD will NOT have abnormal albuminuria
 Prognosis
− Important prognostic marker, especially in diabetes mellitus
(DM)
− Used to monitor and guide therapy (but note ACP guidelines)
 Tool for patient education and self-management (such as
A1C or eGFR)
Urine albumin results are used for screening,
diagnosing, and treating CKD

Definition of Albuminuria
Method Normal
Micro-
albuminuria
Overt/Macro-
albuminuria
24 hour excretion <30 mg/day 30-300 mg/day >300 mg/day
Timed urine specimen <20 g/min 20-200 g/min >200 g/min
Spot-urine albumin
specific dipstick
(screening)
<3 mg/dl >3 mg/dl N/A
Spot urine albumin/
creatinine ratio (ADA)
< 30 mg/g 30-300 mg/g >300 mg/g
Spot urine albumin/
creatinine ratio (gender
specific) (K/DOQI)
<17 mg/g (men)
<25 mg/g (women)
17-250 (men)
25-355 (women)
>250 (men)
>355 (women)
K/DOQI and ADA

 Dipstick
− Semi-quantitative, screening only
 Affected by urine concentration, highly variable
− Detection of urine albumin > 300 mg/day
(1+ approximates albumin excretion of 30 mg/day)
 Urine protein/creatinine ratio
‒ All proteins, not just albumin (myeloma/CIN)
 Urine albumin-to-creatinine ratio (UACR)
‒ Quantifies urine albumin
− Steps toward standardization currently in progress
− Standard for public health, clinical care, and research
Which urine test to use?

Hypertension, diabetes
and elevated creatinine
• 75 y/o female with long
standing hypertension
and diabetes.
• To her knowledge, she
has not had any kidney
problems previously.
• MRI/MRA small kidney
approximately 9 cm
bilaterally.
Lab parameter Value
Serum Creatinine 1.9 mg/dL
BUN 46 mg/dL
Hemoglobin 12.1 g/dL
HbA1c 8.1%
Albumin:Creatinine
Ratio
250

Patient with hypertension
What is her kidney
function?
Lab parameter Value
Serum Creatinine 1.9 mg/dL
BUN 46 mg/dL
Pick your preferred
equation to calculate
her GFR…
• 100/Scr = 45.4
• Cockroft-Gault = 25
ml/min
• CKD-EPI = 25 ml/min
• MDRD = 28 ml/min
• 24-hour urine collection
= 27 ml/min

Patient with hypertension
How can we characterize her kidney function?
– Cause: Type 2 Diabetes
Albumin
• 135 mg/g
GFR
• 100/Scr = 45.4
• C-G = 25 ml/min
• CKD-EPI = 28 ml/min
• MDRD = 28 ml/min
• 24-hour urine = 27 ml/min
High Risk of Progression

ACP Guidelines
• Recommendation 1: ACP recommends against screening for chronic kidney
disease in asymptomatic adults without risk factors for chronic kidney disease.
– (Grade: weak recommendation, low-quality evidence)

• Recommendation 2:
ACP recommends against
testing for proteinuria in
adults with or without
diabetes who are
currently taking an
angiotensin-converting
enzyme inhibitor or an
angiotensin II–receptor
blocker.
– (Grade: weak
recommendation, low-
quality evidence)
– Residual albuminuria in
fixed dose ARB trials:
increased renal risk
ACP Guidelines

ACP Guidelines
• Recommendation 3:
ACP recommends that clinicians select pharmacologic therapy
that includes either an angiotensin-converting-enzyme
inhibitor (moderate-quality evidence) or angiotensin II–
receptor blocker (high-quality evidence) in patients with
hypertension and stage 1 to 3 chronic kidney disease.
– (Grade: strong recommendation)
• The risk for ESRD was not reduced in patients with only microalbuminuria or
impaired GFR.
• Pooled data from 10 trials showed that mortality risk was reduced in patients
with microalbuminuria, although most of the data were derived from a large
study that showed no difference in mortality between patients with and without
microalbuminuria.
• Therapy with ACE inhibitors did not reduce the risk for cardiovascular mortality,
myocardial infarction (MI), stroke, or other vascular outcomes.

Benazepril effective in advanced CKD
• Findings consistent with earlier
results from REIN Trial (Ruggenenti
2001) and systematic review (Bakris
2000).
• Cough 17% in run in period, >30%
bump in creatinine 2%.
• NNT with benazepril 5-6 for
composite outcome of doubling
creatinine, ESRD, death (Hsu ACP
Journal Club).
• Shows that benazepril safe and
effective in advanced non-DM CKD.Hou NEJM 2006

ACP Guidelines
• Recommendation 4: ACP recommends that clinicians
choose statin therapy to manage elevated low-
density lipoprotein in patients with stage 1 to 3
chronic kidney disease.
– (Grade: strong recommendation, moderate-quality evidence)

Moderately Elevated Systolic Blood Pressure
Combined With Normal Diastolic Blood
Pressure Had Consistently Lower Mortality
Rates Among U.S. Veterans With CKD
• Kovesdy CP, Bleyer AJ, Molnar MZ, et al. Blood pressure and
mortality in U.S. veterans with chronic kidney disease: a
cohort study. Ann Intern Med. 2013;159:233-42.
• The BP targets for patients with CKD have been unclear and
may differ by severity of proteinuria or diabetes status.

US VA CKD Cohort Outcomes
• The relationship of both SBP and
DBP with mortality was
U-shaped.
• Various combinations of lower
SBPs and DBPs were associated
with lower mortality rates as
long as the DBP remained
greater than approximately 70
mm Hg.
• Patients with SBP of 130-159 mm
Hg and DBP of 70-89 mm Hg had
the lowest mortality rates.
• Patients with “ideal” BP
(<130/80 mm Hg) had increased
mortality rates because the
study included patients with low
SBPs and DBPs.

Implications
• This study challenges guidelines recommending lower BP
targets for patients with CKD.
• These findings are consistent with the Eighth Joint National
Committee recommendations.
– Recommendation 4 in the population aged ≥18 years with
CKD, initiate pharmacologic treatment to lower BP at
SBP ≥140 mm Hg or DBP ≥90 mm Hg and treat to goal
SBP <140 mm Hg and DBP <90 mm Hg.
(Expert Opinion – Grade E)
• Further information on BP targets will be provided by SPRINT
(Systolic Blood Pressure Intervention), an ongoing trial by the
National Institutes of Health that examines BP targets in older
adults with and without CKD.

Relaxation of CKD BP Target
Guidelines
Group Goal BP Initial
Therapy
Group Goal BP Initial
Therapy
ADA 2009 <130/80 ACE/ARB ADA 2013 ≤140/90 ACE/ARB
JNC 7 <130/80 ACE/ARB JNC 8 <140/90 ACE/ARB
KDOQI
(2007)
<130/80 ACE/ARB KDIGO
2013
<140/90 ACE/ARB
<130/80 proteinuria
Am Society
of HTN
2008
≤130/80 ACE/ARB ASH/ISH
2013
<140/90 ACE/ARB
<130/80 Some
experts for
proteinuria

SPRINT Important Goals
https://sprint.phs.wfubmc.edu
• SPRINT will test whether a treatment strategy aimed at
reducing SBP to a lower goal (< 120 mm Hg) than currently
recommended (< 140 mm Hg) will reduce the occurrence of
cardiovascular (CVD) and CKD events.
• SPRINT Memory and cognition In Decreased Hypertension
(MIND) will test whether the lower SBP goal influences the
occurrence of dementia, change in cognition, and change in
brain structure.

INTERFACE BETWEEN PRIMARY
CARE AND NEPHROLOGY

Lifestyle modifications help lower blood
pressure in the general population
References: Chobanian et al. J Am Med Assoc 2003; 289(19):2560–2571;
Neter et al. Hypertension 2003; 42(5):878–884; Dietary Guidelines, 2010
Modification Recommendation Lowers Systolic Blood
Pressure by (Range)
Weight reduction •Maintain normal body weight
•Body mass index (BMI) 18.5–24.9
kg/m2
5–20 mm Hg /  10 kg
 4 mm Hg /  5 kg
DASH •Increase potassium (fruits and
vegetables) and calcium (dairy)
•DASH may be too high in protein,
potassium and phosphorus for CKD
8–14 mm Hg
Physical activity •At least 30 minutes most days 4–9 mm Hg
Moderate alcohol
consumption
•Women: ≤ 1 drink per day
•Men: ≤ 2 drinks per day
2–4 mm Hg
Sodium restriction •2,300 mg per day
•1,500 mg per day for hypertension,
diabetes, and CKD
2–8 mm Hg
Modification Recommendation Lowers Systolic Blood
Pressure by (Range)
Weight reduction •Maintain normal body weight
•Body mass index (BMI) 18.5–24.9
kg/m2
5–20 mm Hg /  10 kg
 4 mm Hg /  5 kg
DASH •Increase potassium (fruits and
vegetables) and calcium (dairy)
•DASH may be too high in protein,
potassium and phosphorus for CKD
8–14 mm Hg
Physical activity •At least 30 minutes most days 4–9 mm Hg
Moderate alcohol
consumption
•Women: ≤ 1 drink per day
•Men: ≤ 2 drinks per day
2–4 mm Hg
Sodium restriction •2,300 mg per day
•1,500 mg per day for hypertension,
diabetes, and CKD
2–8 mm Hg

CKD and hypertension
 BP ≤ 140/90 may be
beneficial for many
 Nephrologists like ≤ 130/80
for proteinuria (for now)
 Multiple medications (>2-3)
 Most will need a diuretic
Assessment:
 Food–medication interaction
− Hyperkalemia
Intervention:
 Limit sodium
− Keep to ≤ 1,500 mg/day
(? harm in DM w/o CKD)
− Avoid salt substitutes
 Limit potassium when
serum level is elevated
− Individualized
 Most CKD patients will not
become hypokalemic when
treated with a diuretic

 Renal threshold for glucose is 180–200 mg/dL.
 Sugars cross-linking to proteins changes their shapes and
functions (AGEs).
 A1C goal is individualized (≤ 7% in ADA 2014).
 Spontaneous improvement in glycemic control may
indicate CKD progression and medications may change.
 Risk for hypoglycemia occurs with CKD (insulin is cleared
from the kidneys, 20% of gluconeogenesis occurs in the
kidney); risk for hyperkalemia occurs with ACEi and
ARBs.
− Use low-potassium juice to treat hypoglycemia.
− Light-colored soda pop is lower in phosphorus than cola.
CKD and diabetes I

Any “juice” can treat hypoglycemia, even
those low in potassium
mg

 Urine albumin excretion is associated with diabetic kidney
disease, but not all people will have high urine albumin
levels.
 High levels of urine albumin may mean more rapid
progression of CKD.
 Good control of diabetes early may help reduce the risk of
albuminuria later.
 Tight versus good control may not slow progression
 Potential dangers associated with very tight control and
sodium restriction
CKD and diabetes II

 Same traditional factors as the general population
 Also Nontraditional risk factors which include:
− Albuminuria
− Anemia
− Abnormal calcium and phosphorus metabolism
 Statins are used in CKD patients with some caution
(ezetimibe/simvastatin may be more beneficial: off label)
 Some foods rich in soluble fiber may be higher in K and P
than recommended for CKD patients.
 Phosphorus in food additives is absorbed much more
readily.
CKD and CVD

 Control blood pressure (ACEi/ARB)
 Reduce sodium intake (but note emerging data
about possible harms in diabetics)
 Achieve good control of diabetes early; may help
prevent albuminuria
 Reduce weight (if obese)
 Reduce protein intake, if excessive
 Achieve tobacco cessation
Interventions for reducing urine albumin

Drug Dosing Considerations
• Renal impairment may alter both pharmacodynamics and
pharmacokinetics
• There is a higher risk for Adverse Drug Reactions as a result of renal
functional impairment AND comorbidities in CKD patients
• Drug development programs and the FDA lag behind clinical
practice when quantifying renal function and risk (MeDRA uses
creatinine elevation, studies are designed based on Cockroft Gault)
• MOST DRUGS HAVE NEVER BE TESTED IN CKD POPULATIONS
• Dosing recommendations are often based on post-hoc analyses or
PK/PD modeling using “general population” relationships
• One is often conducting an RCT n=1 when prescribing a medication
in CKD

Cockroft Gault ≠ MDRD for drug dosing
Ann Pharmacother 2012;46:1174-87
For patients with advanced age, low weight, and modestly elevated serum
creatinine, further work is needed before the MDRD equations can replace
the CG equation for dose adjustment in the labeling.

Renal function estimation formulas
for drug dosing
Pharmacotherapy. 2011;31(11):1130-1144.

The
cautious
approach
to drug
dosing in
CKD
Pharmacotherapy. 2011;31(11):1130-1144.

 Glyburide
 Metformin (US label SCr>1.4-
1.5 ex-US eGFR>30)
 Alpha-glucosidase inhibitors
 Exenatide
 Glimepiride
 Sitagliptin
 Repaglinide
 Insulin (dose decrease)
 Glipizide
 Pioglitazone
− Fluid retention (bladder cancer, ↑
risk of CKD?)
 Nateglinide
 Pramlintide
 SGLT2 inhibitors:
− Canaglifozin
(Invokana)/empaglifozin
(Jardiance) (stop if eGFR<45)
− Dapaglifozin(Farxiga) (stop if
eGFR<60)
Diabetes medications may be
discontinued or adjusted in CKD
Reference: Reilly & Berns Seminars in Dialysis 2010; 23(2):163–168.
Farxiga/Invokana/Jardiance PIL

 Alternatives to warfarin that are licensed for use
without Therapeutic Drug Monitoring
− Rivaroxaban (Xarelto) : Xa inhibitor
− Apixaban (Eliquis): Xa inhibitor
− Dabigatran (Pradaxa): DRI
 No dietary restrictions compared to Coumadin
 Rapidly expanding clinical use
 Safety signals for older individuals with renal
impairment
 They are removed by the kidneys
 Dialytic clearance substantial only for dabigatran
Novel Oral AntiCoagulants (NOACs) in CKD

Safety of NOACs in CKD (major or
clinically relevant bleeding)
eGFR(50-79) eGFR(30-49)

Efficacy of NOACs in mild CKD
(eGFR 50-79)
Stroke VTE or VTE related death

Efficacy of NOACs in moderate
CKD (eGFR 30-49)
Stroke VTE or VTE related death

NOACs – Dosing Recommendations
• Apixaban 2.5 mg- 10mg BID
– 2.5 mg BID if one of the following (Wt<60 kgr, age>80), SCr > 1.5 mg/dl
• Dabigatran 150 mg BID
– 75 mg BID if CrCl 15-30 ml/min
• Rivaroxaban 10 -20 mg QD
– VTE prophylaxis (use w caution for ClCr 30-50, avoid for ClCr < 30)
– Afib: 20mg/d (ClCr > 50), 15 mg/d (15-50 ml/min, avoid for ClCr <15)
• NOACs not recommended for non dialysis dependent CKD
stage V (ClCr < 15)
• In patients on dialysis may only use Apixaban:
– 5 mg po BID unless one of the following (Wt<60 kgr, age>80): use 2.5
mg bid

Medications that increase risk for
hyperkalemia in CKD
Referece: Chobanian et al. J Am Med Assoc 2003; 289(19):2560–2571
Commonly prescribed
 Angiotensin-Converting
Enzyme Inhibitor (ACEi)
 Angiotensin Receptor
Blockers (ARB)
Used cautiously in CKD
 Aldosterone antagonists
 Renin inhibitors
 Potassium-sparing
diuretics
Whenever an ACEi/ARB/Aldo antagonist/DRI is started
check K within 7-10 days (but not sooner than 7 or >14)
K-sparing diuretics in CKD or diabetes (with normal
eGFR/proteinuria): check K within 3-7 days (but not later)

The role of the nephrologist outside the
dialysis unit
• Treating complications of CKD
• Slowing progression
• Preparation for renal replacement therapy:
– Outpatient hemodialysis
– Home hemodialysis
– Peritoneal dialysis (home therapy)
– Pre-emptive renal transplantation

 Fewer functioning nephrons may mean:
− Inadequate erythropoietin (anemia)
− Accumulation of potassium (K)
− Accumulation of hydrogen ion (metabolic acidosis)
− Inadequate activation of vitamin D (bone disease)
− Accumulation of phosphorus (P)
− Accumulation of pro-inflammatory cytokines
 Toxins build up in the blood.
Complications increase as kidney
function declines

Complications may increase as estimated
glomerular filtration rate (eGFR) decreases
Reference: Adapted from USRDS 2010 Annual Data Report (NIDDK, 2010)

• Delivered by a CKD educator (usually a RN) meeting
face to face with the patient
• Increase number of pts. receiving early (stage 3 & 4)
CKD education statewide.
• Prevent “traumatic dialysis starts”: decrease catheter
placement rate, increase fistula placement and PD
catheter placement rate.
• Increase number of pts. choosing Home Dialysis.
• Slow progression of CKD and delay need for dialysis.
• Prevent dialysis through pre-emptive transplant.
IT IS NOT JUST ABOUT THE
NEPHROLOGIST: CKD EDUCATION
PROGRAM OBJECTIVES

What else is out there?
(all these are off label)
• VDRAs (calcitriol, paricalcitol, doxercalciferol) for proteinuria
(GNs/DM)
• Uric acid modulation
• Alkali therapy for acidosis
• Pentoxifylline
• SGLT2 (early stage DN: in clinical trials)
• Aldosterone antagonists (in combination with ACEi/ARBs: not
undertaken lightly)
• K-sparing diuretics for tx resistant volume overload in
proteinuria(not undertaken lightly – UNM clinical trial
experience: NCT01804777)
• DRIs (Direct Renin Inhibitors)
• ETR- A antagonists (in clinical trials)

Interface between
PC and Nephrology
KDIGO guidelines

CKD Checklist for PCPs
• Slowing Progression
– BP < 140/90
– HBA1c ≤ 7% within 6 mos
– Annual screen for proteinuria
– On ACEi/ARB if DM or microalb
> 30mg/g
– Smoking cessation
– Discuss avoidance of
NSAIDs/nephrotoxins
– LDL < 100 within the last year
– 5 year pneumovax
– Yearly flu
• Tx of Complications
– CBC, iron studies within the
year
– Ca, P, PTH (q 6 mo if eGFR <
60, q 3 mo if eGFR < 30)
• Nephrology Referral
– GFR < 30
– Persistent proteinuria
despite ACEi
– Persistent hyperK
– Resistant HTN (≥4 meds)
– ↓GFR by 30% (“certain
drop”) irrespective of eGFR
– Unclear etiology of CKD
– Anemia requiring ESAs
– ↑ P, PTH
CJASN 9:1526-1535, 2014

Chronic Kidney Disease in Primary Care

Empfohlen

Empfohlen

Weitere ähnliche Inhalte

Was ist angesagt?

Was ist angesagt? (20)

Ähnlich wie Chronic Kidney Disease in Primary Care

Ähnlich wie Chronic Kidney Disease in Primary Care (20)

Mehr von Christos Argyropoulos

Mehr von Christos Argyropoulos (20)

Chronic Kidney Disease in Primary Care